Targeted molecular therapy of malignant gliomas

被引：48
作者：
Kesari S. [1 ]
Ramakrishna N. [1 ]
Sauvageot C. [1 ]
Stiles C.D. [1 ]
Wen P.Y. [1 ]
机构：
[1] Center For Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center, Boston, MA 02115
来源：
Current Neurology and Neuroscience Reports | 2005年 / 5卷 / 3期
关键词：
Epidermal Growth Factor Receptor; Imatinib; Gefitinib; Erlotinib; Malignant Glioma;
D O I：
10.1007/s11910-005-0046-8
中图分类号：
学科分类号：
摘要：
Malignant gliomas are the most common form of primary brain tumors in adults. Despite advances in diagnosis and standard therapies such as surgery, radiation, and chemotherapy, the prognosis remains poor. Recent scientific advances have enhanced our understanding of the biology of gliomas and the role of tyrosine kinase receptors and signal transduction pathways in tumor initiation and maintenance, such as the epidermal growth factor receptors, platelet-derived growth factor receptors, vascular endothelial growth factor receptors, and the Ras/Raf/mitogen-activated protein (MAP)-kinase and phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathways. Novel targeted drugs such as small molecular inhibitors of these receptors and signaling pathways are showing some activity in initial studies. As we learn more about these drugs and how to optimize their use as single agents and in combination with radiation, chemotherapy, and other targeted molecular agents, they will likely play an increasing role in the management of this devastating disease. This review summarizes the current results with targeted molecular agents in malignant gliomas and strategies under evaluation to increase their effectiveness. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：186 / 197
页数：11
相关论文
共 113 条
  • [1] Primary Brain Tumors in the United States, 1997-2001, (2004)
  • [2] Kleihues P., Cavenee W.K., Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumors, (2000)
  • [3] Fiveash J.B., Spencer S.A., Role of radiation therapy and radiosurgery in glioblastoma multiforme, Cancer J., 9, pp. 222-229, (2003)
  • [4] Wen P.Y., Kesari S., Malignant gliomas, Curr. Neurol. Neurosci. Rep., 4, pp. 218-227, (2004)
  • [5] Mrugala M.M., Kesari S., Ramakrishna N., Wen P.Y., Therapy for recurrent malignant glioma in adults, Expert Rev. Anticancer Ther., 4, pp. 759-782, (2004)
  • [6] Stupp R., Mason W.P., van den Bent M.J., Et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med., 352, pp. 987-996, (2005)
  • [7] Konopka G., Bonni A., Signaling pathways regulating glioma-genesis, Curr. Mol. Med., 3, pp. 73-84, (2003)
  • [8] Mischel P.S., Nelson S.F., Cloughesy T.F., Molecular analysis of glioblastoma: Pathway profiling and its implications for patient therapy, Cancer Biol. Ther., 2, pp. 242-247, (2003)
  • [9] Maher E.A., Furnari F.B., Bachoo R.M., Et al., Malignant glioma: Genetics and biology of a grave matter, Genes Dev., 15, pp. 1311-1333, (2001)
  • [10] Nabors L.B., Targeted molecular therapy for malignant gliomas, Curr. Treat. Options Oncol., 5, pp. 519-526, (2004)
12345678910